NCT03425526View on ClinicalTrials.gov

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
Hematopoietic and Lymphoid Cell NeoplasmImmunocompromised
Interventions
BIOLOGICAL

Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER